Health
-
Saxenda® provides consistent weight loss and improvements in blood glucose control across BMI categories after three years of treatment
Sep 15, 2016News Hour: Saxenda® (liraglutide 3 mg) is a once-daily glucagon-like peptide-1 (GLP-1) analogue with 97% similarity to naturally occurring human GLP-1,10 a hormone that is released in response to food intake. Results from a post hoc... -
Vitamin D shown to improve insulin sensitivity in a model of diet-induced insulin resistance
Sep 15, 2016News Hour: Giving vitamin D improves insulin sensitivity in mice that have become insulin resistant due to a chronic high fat high sugar diet. Vitamin D also reduces the accumulation of fat in muscles (myosteatosis), another... -
High levels of depression among patients with type 2 diabetes
Sep 15, 2016News Hour: High rates of depressive disorder (10%) in patients with type 2 diabetes, with wide variations between countries. This analysis of the INTERPRET-DD study is by Professor Catherine Lloyd, The Open University, Milton Keynes, UK,... -
Pancreatic cancer could be detected early in patients with newly developed type 2 diabetes
Sep 15, 2016News Hour: Screening patients newly diagnosed with diabetes for pancreatic cancer could be an effective way of diagnosing and treating pancreatic cancer early. The study is by Dr Pavel Škrha, Charles University, Prague, Czech Republic and... -
Long daytime naps of 1 hour or more increase risk of developing diabetes by 45%
Sep 15, 2016News Hour: Latest research presented at this year’s European Association for the Study of Diabetes (EASD) meeting in Munich, Germany (12-16 Sept) shows that daytime naps of over 1 hour or more increase the risk of developing... -
Adults with type 2 diabetes treated with Xultophy® (IDegLira) were up to 4.5 times more likely to reach glycaemic targets without hypoglycaemia
Sep 15, 2016News Hour: Novo Nordisk presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly greater for Xultophy® (IDegLira) compared to up-titration with insulin glargine U100 in adults... -
Semaglutide demonstrated superior HbA1c reduction vs placebo as add-on to basal insulin alone
Sep 15, 2016News Hour: Semaglutide is a once-weekly investigational analogue of human glucagon-like peptide-1 (GLP-1) that stimulates insulin and suppresses glucagon secretion in a glucosedependent manner, while decreasing appetite and food intake. Novo Nordisk announced that semaglutide, an... -
Asterias stem cell therapy shows promise in spinal cord paralysis
Sep 15, 2016News Hour: An experimental stem cell therapy developed by Asterias Biotherapeutics restored some movement to patients paralyzed by recent spinal cord injuries, according to interim data from a small study being presented on Wednesday. One of... -
Shire’s treatment for primary immunodeficiency wins FDA approval
Sep 15, 2016News Hour: Shire Plc said the United States Food and Drug Administration (FDA) approved its treatment for patients with primary immunodeficiency, a group of genetic disorders in which part of the body’s immune system is missing... -
U.N. panel challenges market-based approach to drug R&D
Sep 15, 2016News Hour: The world cannot rely solely on free markets to deliver medicines needed by billions of people in poor countries, so governments should commit to a legally binding convention to coordinate and fund research and...
